bpc 157 endometriosis and Peptide Therapy: Pain and Inflammation GLP-1 and endometriosis: what the

Published 2007 Jan 1

5-Amino-1MQ inhibits the NNMT enzyme to theoretically raise NAD+ levels and improve insulin sensitivity, but evidence is limited to preclinical animal studies only

Response: We thank commenters for providing additional suggestions with respect to this proposal, and, as we have explained, we are finalizing modifications to the proposal that we believe address several commenters' concerns

Safety: what we know, what we dont What clinical trial safety reviews suggest The clinical safety review literature reports several reassuring signals: No meaningful increase in IGF-1 in monitored long-term studies (jofem.org) No clear negative effect on carbohydrate metabolism in testing described (contrast with full hGH) (jofem.org) No clear immunogenicity signal (e.g., anti-AOD antibodies) in the subset assessed in those trials (jofem.org) The major limitation: long-term real-world certainty is thin The problem with many peptides is not that everything is dangerousits that the certainty level is often lower than patients assume